Dundalk, Ireland – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development, and manufacturing, announced that its subsidiary WuXi Vaccines, engaged in human vaccine Contract Development and Manufacturing Organization (CDMO) business, is to invest 240 million USD and build a new vaccine manufacturing facility in Ireland. This investment follows the 20-year manufacturing Letter of Intent (LOI) signed by WuXi Vaccines earlier this year.
Under the LOI, this new dedicated vaccine manufacturing facility, including drug substance manufacturing (MFG15), drug product manufacturing (DP5) as well as Quality Control labs (QC), will supply a vaccine product of a large global pharma for the global market. The new vaccine manufacturing facility, subject to planning approval, will be located within the WuXi Biologics Campus adjacent to the “Factory of the Future” biologics drug substance manufacturing facility which is scheduled for commercial manufacturing in 2021.
Heather Humphreys T.D., Minister for Business, Enterprise and Innovation of Ireland, said, “I am delighted to announce 200 highly-skilled jobs in WuXi Vaccines, which is in addition to the 400 roles announced last year by WuXi Biologics for Dundalk. Today’s announcement demonstrates, once again, that the Border region is a very attractive location in which to invest.”
Eileen Sharpe, Divisional Manager Growth Markets, Europe and Emerging Business at Industrial Development Authority (IDA) Ireland, commented, “A second major investment by WuXi Biologics on its Dundalk site is very welcome news. As the first vaccines contract manufacturing facility in Ireland, this planned second project will considerably strengthen our life sciences ecosystem and reinforce Ireland’s strong manufacturing capabilities.”
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of WuXi Vaccines, commented, “We’re excited to dedicate our first vaccine manufacturing facility in Ireland to enable a large global pharma in the field of vaccines. Due to process complexity, extensive analytic testing and rigorous regulatory standards, vaccines are difficult to manufacture, and process and quality control are extremely critical for the quality of the product. This new project to exclusively manufacture a vaccine for a global large pharma to supply the global market is among the first of its kind in the industry and is a further testimony to the technical strengths, premier quality, and commercial manufacturing expertise which WuXi Biologics will bring to Dundalk. WuXi Biologics, together with WuXi Vaccines, is continuing providing our global partners with a robust and premier-quality supply chain network to produce high-quality biologics to benefit patients worldwide.”
PureCycle’s First Plastic Recycling Plant in Europe located in Antwerp-Brugges NextGen District, Belgium
The new plant is expected to have an annual capacity of 59,000 metric tons, with opportunities to expand operations with an anticipated total capacity of approximately 240,000 metric tons per year.
CABB site in Kokkola, Finland: vital growth with a focus on sustainability
CABB Group will invest more than EUR 50 million by 2025 in expanding its facilities at its site in Kokkola, Finland. A new office building is also being constructed. Special attention is being pai...
TotalEnergies commissions BioBéarn, the country’s largest anaerobic digestion unit in Mourenx, France
The project will convert 220,000 metric tons of organic waste into 200,000 metric tons per year of digestate, a natural fertilizer, and 160 GWh of biomethane. This new unit allowing to avoid the em...
Borealis, committed to lead the transformation to a circular economy, acquires a majority stake in Renasci’s Ostend facility, Belgium
Borealis increases its financial investment in Renasci to acquire a majority shareholding position of 50.01%. Investment will provide Borealis increasing access to chemically recycled feedstock, st...